Market closedNon-fractional
Crinetics Pharmaceuticals/CRNX
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Ticker
CRNX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
San Diego, United States
Employees
290
Website
www.crinetics.com
CRNX Metrics
BasicAdvanced
$3.6B
Market cap
-
P/E ratio
-$3.76
EPS
0.63
Beta
-
Dividend rate
Price and volume
Market cap
$3.6B
Beta
0.63
Financial strength
Current ratio
17.718
Quick ratio
17.584
Long term debt to equity
5.339
Total debt to equity
6.001
Management effectiveness
Return on assets (TTM)
-24.01%
Return on equity (TTM)
-40.76%
Valuation
Price to revenue (TTM)
1,445.71
Price to book
4.08
Price to tangible book (TTM)
4.08
Price to free cash flow (TTM)
-15.47
Growth
Revenue change (TTM)
-53.93%
Earnings per share change (TTM)
14.98%
3-year earnings per share growth
15.62%
What the Analysts think about CRNX
Analyst Ratings
Majority rating from 14 analysts.
CRNX Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$600K
∞%
Net income
-$67M
11.50%
Profit margin
-11,150.00%
-∞%
CRNX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.94
-$1.01
-$0.90
-$0.93
-
Expected
-$0.86
-$0.86
-$0.86
-$0.81
-$0.86
Surprise
9.61%
17.59%
4.36%
14.90%
-
CRNX News
AllArticlesVideos
EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner
GlobeNewsWire·2 weeks ago
Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·3 weeks ago
Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing's Syndrome (ADCS)
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Crinetics Pharmaceuticals stock?
Crinetics Pharmaceuticals (CRNX) has a market cap of $3.6B as of July 04, 2024.
What is the P/E ratio for Crinetics Pharmaceuticals stock?
The price to earnings (P/E) ratio for Crinetics Pharmaceuticals (CRNX) stock is 0 as of July 04, 2024.
Does Crinetics Pharmaceuticals stock pay dividends?
No, Crinetics Pharmaceuticals (CRNX) stock does not pay dividends to its shareholders as of July 04, 2024.
When is the next Crinetics Pharmaceuticals dividend payment date?
Crinetics Pharmaceuticals (CRNX) stock does not pay dividends to its shareholders.
What is the beta indicator for Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals (CRNX) has a beta rating of 0.63. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Crinetics Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.